{"id":554083,"date":"2021-07-22T21:40:02","date_gmt":"2021-07-22T21:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=554083"},"modified":"2021-07-22T21:40:02","modified_gmt":"2021-07-22T21:40:02","slug":"ascites-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ascites-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_554083.html","title":{"rendered":"Ascites Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1626939055.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ascites Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1626939055.jpeg\" alt=\"Ascites Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Ascites Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Ascites market. A detailed picture of the Ascites pipeline landscape is provided, which includes the disease overview and Ascites treatment guidelines.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ascites-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;<strong>Ascites Pipeline Insight&rdquo;<\/strong><\/a> report provides comprehensive insights about key companies&nbsp;and pipeline drugs in the Ascites pipeline landscapes. It comprises Ascites pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Ascites therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Ascites pipeline products.&nbsp; &nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/b8c3ad1220aa2c4c17955217abdb9549.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways of the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ascites-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Ascites Pipeline Report<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as<\/span><span data-mce-mark=\"1\">Grifols S.A., BioVie Inc., Noorik Biopharmaceuticals, Clover Biopharmaceuticals, <\/span><span data-mce-mark=\"1\">etc., are developing therapies for the treatment of Ascites.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Emerging therapies such as <\/span><span data-mce-mark=\"1\">Albutein 20% Injectable Solution, BIV201, N-003, SCB-313, <\/span><span data-mce-mark=\"1\">are expected to have a significant impact on the <\/span><span data-mce-mark=\"1\">&nbsp;Ascites <\/span><span data-mce-mark=\"1\">market in the coming years.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The growing incidence of Ascites is predicted to drive the expansion of the Ascites market.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">The rise in the prevalence of cirrhosis and alcohol consumption is anticipated to drive the Ascites market.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ascites-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Ascites Clinical Trials Analysis<br \/><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">When over 25 millilitres (mL) of fluid builds up inside the abdomen, it&rsquo;s referred to as ascites. Ascites usually occur when the liver stops working properly. When the liver malfunctions, fluid fills the space between the abdominal lining and therefore the organs.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cirrhosis of the liver is the most typical reason behind ascites, but other conditions like heart failure, kidney failure, infection, or cancer also can cause the disease. Ascites are caused by a mixture of elevated pressure within the veins running through the liver (portal hypertension) and a decrease in liver function caused by scarring of the liver, i.e., cirrhosis.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Ascites Emerging Drugs<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Albutein 20% Injectable Solution by <\/span><span data-mce-mark=\"1\">Grifols S.A.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">BIV201 by <\/span><span data-mce-mark=\"1\">BioVie Inc.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">N-003 by <\/span><span data-mce-mark=\"1\">Noorik Biopharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">SCB-313 by <\/span><span data-mce-mark=\"1\">Clover Biopharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">And others.<\/span><\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Scope of Ascites Pipeline Drug Insight&nbsp; &nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Major Players:<\/span><span data-mce-mark=\"1\">Grifols S.A., BioVie Inc., Noorik Biopharmaceuticals, Clover Biopharmaceuticals, <\/span><span data-mce-mark=\"1\">and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Pipeline Therapies:<\/span><span data-mce-mark=\"1\"> Albutein 20% Injectable Solution, BIV201, N-003, SCB-313, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">1<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">2<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">3<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">4<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">5<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">6<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Late Stage Products (Phase II\/III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">7<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">8<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Early Stage Products (Phase I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">9<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Preclinical Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">10<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Therapeutics Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">11<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">12<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">13<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">14<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">15<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">16&nbsp;<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">17<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">18<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Ascites Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">19<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">20<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span data-mce-mark=\"1\">About DelveInsight<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ascites-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Ascites Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s Ascites &#8211; Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Ascites, historical and forecasted epidemiology as well as the Ascites market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ascites-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Ascites Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216; Ascites- Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted&nbsp; Ascites epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ascites-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ascites-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Ascites Pipeline Insights, 2021&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Ascites market. A detailed picture of the Ascites pipeline landscape is provided, which includes the disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ascites-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_554083.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-554083","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=554083"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/554083\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=554083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=554083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=554083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}